As previously reported, Benchmark analyst Bill Sutherland upgraded Omnicell to Buy from Hold with a $68 price target ahead of the company’s earnings release due on the night of February 28. The firm believes management will set 2023 guidance "conservatively" and start the process of rebuilding credibility with investors after last quarter’s "shocking" guide down. Benchmark, which does not expect a significant step down, if any, from consensus, sees potential upside in bookings guidance, given that it thinks consensus in this area is "overly conservative," the analyst added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OMCL:
- Omnicell should be bought on any earnings weakness, says Piper Sandler
- Omnicell price target lowered to $70 from $75 at KeyBanc
- Omnicell price target raised to $66 from $55 at Piper Sandler
- Omnicell price target lowered to $65 from $71 at Wells Fargo
- Time to Lean Into These 3 ‘Oversold’ Stocks, Say Analysts
Questions or Comments about the article? Write to editor@tipranks.com